Details

Autor(en) / Beteiligte

• Jung, So-Youn
• Han, Wonshik
• Lee, Jong Won
• Ko, Eunyoung
• Kim, Eunkyu
• Yu, Jong-Han
• Moon, Hyeong-Gon
• Park, In Ae
• Oh, Do-Youn
• Im, Seock-Ah
• Kim, Tae-You
• Hwang, Ki-Tae
• Kim, Sung-Won
• Noh, Dong-Young

Titel

Ki-67 Expression Gives Additional Prognostic Information on St. Gallen 2007 and Adjuvant! Online Risk Categories in Early Breast Cancer

Ist Teil von

• Annals of surgical oncology, 2009-05, Vol.16 (5), p.1112-1121

Ort / Verlag

New York: Springer-Verlag

Erscheinungsjahr

2009

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Background We sought to determine the significance of Ki-67, one of the tumor cell proliferation markers, as a useful prognostic factor in early breast cancer. Methods A total of 1080 consecutive patients with stage I or II breast cancer that underwent surgery between 1998 and 2003 were enrolled. Patients were categorized on the basis of the 2007 St. Gallen consensus and Adjuvant! Online. The expression of Ki-67 in the tumor was assayed by immunohistochemistry (cutoff value, 10%). Results Univariate analysis determined that tumor size, lymph node involvement, histologic grade, estrogen receptor, progesterone receptor, bcl-2, and Ki-67 (≥10%) were statistically significant for both overall survival (OS) and distant metastasis-free survival (DFS). Of these factors, lymph node involvement and high Ki-67 expression were identified as independent prognostic factors for OS and DFS on the basis of multivariate analysis. The survivals of intermediate- and high-risk groups according to 2007 St. Gallen consensus were further separated by Ki-67 expression level (5-year DFS rate = 91.9% vs. 86.3% for Ki-67 < 10% and ≥10%, respectively in intermediate-risk group ( P  = .01); 5-year DFS rate = 82.5% vs. 61.4% for Ki-67 < 10% and ≥10%, respectively in high-risk group ( P  = .01)). The survivals of low- and high-risk groups according to Adjuvant! Online were further separated by Ki-67 expression level (5-year DFS rate = 97.8% vs. 89.5% for Ki-67 < 10% and ≥10%, respectively in low-risk group ( P  = .02); 5-year DFS rate = 9.4% vs. 82.6% for Ki-67 < 10% and ≥10% in high-risk group ( P  = .005)). Conclusions Ki-67 is an independent prognostic factor for DFS and OS in early breast cancer and can provide additional prognostic information on the risk stratification with the use of the 2007 St. Gallen consensus and Adjuvant! Online.